Scientists at The Wistar Institute and the University of Pennsylvania School of Medicine have discovered protein markers that could provide physicians with the first reliable blood test to predict ectopic pregnancies. Their findings are published in the February 16th on-line issue of the Journal of Proteome Research. In a related study of clinical samples, published recently in the journal Fertility and Sterility, the researchers found that one of the proteins – ADAM12 – showed a nearly 97 percent correlation with ectopic pregnancy.
Ectopic pregnancies occur when a woman’s fertilized egg develops outside of the uterus, most often in the Fallopian tubes. As the embryo grows, the tube could rupture, which results in the loss of the embryo and threatens the life of the mother. Ectopic pregnancies occur in about one in 40 to 100 pregnancies. They are the leading cause of death in the first trimester of pregnancy. Currently, diagnosis of ectopic pregnancy relies on the use of ultrasound and there is no single proven blood test.
According to David W. Speicher, PhD, professor and co-leader of Wistar’s Molecular and Cellular Oncogenesis Program and director of the Center for Systems and Computational Biology, in the current study they describe a group of proteins that, “with further refinement, could make a simple blood test for ectopic pregnancy.” Speicher and his team collaborated with Kurt T. Barnhart, MD, MSCE, professor of Obstetrics and Gynecology, at the University of Pennsylvania School of Medicine, associate director of Penn Fertility Care and director of Clinical Research for the Department of Obstetrics & Gynecology .
This current study demonstrates the power of proteomics, or the study of the sum total of proteins that the body is making at a given time, in understanding the state of health or disease in people. Proteomics provides researchers an “unbiased” approach to the discovery of biomarkers, proteins in this case, which could be used to signal the presence of a particular clinical disorder or disease such as ectopic pregnancy.
For more information, please see the Wistar news release: http://www.wistar.org/news_info/pressreleases/pr_02.17.11.htm .
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.